Randomized controlled trial of KW-6356 monotherapy in patients with early untreated Parkinson's disease

KW-6356 is a novel selective adenosine A2A receptor antagonist/inverse agonist. We evaluated the efficacy and safety of KW-6356 as monotherapy in patients with early, untreated Parkinson's disease (PD).

Source: Parkinsonism and Related Disorders - October 30, 2023 Category: Neurology Authors: Maeda Tetsuya, Takashi Kimura, Kenichiro Sugiyama, Kana Yamada, Ren Hiraiwa, Masato Nishi, Nobutaka Hattori, 6356-002 study group Source Type: research